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Abstract
AIM: To evaluate cladribine [2-chlorodeoxyadenosine 
(2-CdA)] therapy in refractory celiac disease (RCD) Ⅱ.  
METHODS: An open-label cohort-study of RCD Ⅱ pa-
tients treated with 2-CdA was performed between 2000 
and 2010. Survival rate, enteropathy associated T-cell 
lymphoma (EATL) occurrence, clinical course, and his-
tological and immunological response rates were evalu-
ated. 
RESULTS: Overall, 32 patients were included with a 
median follow-up of 31 mo. Eighteen patients respond-
ed well to 2-CdA. Patients responsive to 2-CdA had a 
statistically significant increased survival compared to 
those who were unresponsive. The overall 3- and 5-year 
survival was 83% in the responder and 63% and 22% 
in the non-responder group, respectively. The overall 
2-year clinical, histological and immunological response 
rates were 81%, 47% and 41%, respectively. Progres-
sion into EATL was reported in 16%, all of these pa-
tients died. 
CONCLUSION: Treatment of RCD Ⅱ with 2-CdA holds 
promise, showing excellent clinical and histological re-
sponse rates, and probably less frequent transition into 
EATL.
© 2011 Baishideng. All rights reserved.
Key words: Cladribine; Refractory celiac disease; Clinical 
course; Enteropathy associated T-cell lymphoma; Survival
Peer reviewer: Hong-Xiang Liu, PhD, Department of Pathol-
ogy, Division of Molecular Histopathology, University of Cam-
bridge, Box 231, Level 3, Lab Block, Addenbrooke’s Hospital, 
Hills Road, Cambridge CB2 2QQ, United Kingdom
Tack GJ, Verbeek WHM, Al-Toma A, Kuik DJ, Schreurs MWJ, 
Visser O, Mulder CJJ. Evaluation of Cladribine treatment in 
refractory celiac disease type Ⅱ. World J Gastroenterol 2011; 
17(4): 506-513  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v17/i4/506.htm  DOI: http://dx.doi.
org/10.3748/wjg.v17.i4.506
INTRODUCTION
Coeliac disease (CD) is characterized by a permanent 
state of  intolerance to dietary gluten leading to an inflam-
matory T-cell response in the small intestine with mu-
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cosal injury in genetically susceptible individuals[1,2]. Al-
though reduction of  this intestinal inflammatory activity 
is usually seen upon strict adherence to a gluten free diet 
(GFD), a small percentage (2%-5%) of  the adult-onset 
CD patients, especially those diagnosed above the age of  
50 years, display a lack of  response to such a diet. They 
are regarded as suffering from refractory celiac disease 
(RCD) when clinical and histological symptoms persist 
or recur after a former good response to a strict GFD, 
despite strict adherence to the diet for more than 12 mo, 
unless earlier intervention is necessary[3,4]. Immunologi-
cally, this syndrome can be subdivided into RCD Ⅰ and 
RCD Ⅱ, with immunophenotypically normal and aber-
rant intraepithelial T lymphocytes (IELs) in the small 
intestinal mucosa, respectively. Clonal expansion of  these 
aberrant IELs, lacking the T-cell surface markers T cell 
receptor (TCR), CD3, CD4 and CD8[5], but expressing 
cytoplasmic CD3, is supposed to be responsible for the 
occurrence of  enteropathy associated T-cell lymphoma 
(EATL)[4-6]. This type of  lymphoma occurs in 60%-80% 
of  RCD Ⅱ patients within 5 years and has a poor prog-
nosis with a 2-year survival of  only 15%[7,8]. The latter 
is mainly due to incomplete response to currently avail-
able therapies, high rates of  life-threatening complica-
tions such as perforation of  the gut, and poor nutritional 
conditions[7,8]. Therefore, it is of  utmost importance to 
evaluate new treatment strategies for RCD Ⅱ in order to 
improve clinical course and prevent or delay progression 
to overt EATL. 
Since the late 90’s, researchers have become increas-
ingly interested in therapeutic alternatives for treating 
RCD Ⅱ, however as far as has been published there is 
no standardised approach yet[9,10]. RCD Ⅱ is, at least in 
part, resistant to most evaluated therapies so far[10-12]. 
Until 2005 in our tertiary referral centre for RCD Ⅱ, 
patients were initially treated with conventional immuno-
suppressive drugs, mainly azathioprine and prednisone, 
and if  clinically and histologically unresponsive cladrib-
ine [2-chlorodeoxyadenosine (2-CdA)] was prescribed. 
Since then, a modified treatment strategy has been initi-
ated with cladribine being drug of  first choice. 
2-CdA is a synthetic purine nucleoside homologue 
being equally toxic to proliferating as to non-dividing 
lymphoid cells. Because of  this unique feature it is sup-
posed to be especially active against low-grade malig-
nancies, including hairy cell leukaemia. Cladribine is 
metabolised into its pharmacologically active cladribine 
triphosphate, which induces apoptosis, necrosis and in-
hibition of  DNA/RNA synthesis (Figure 1). Clinically, 
2-CdA is of  proven value in the treatment of  a num-
ber of  haematological malignancies and selected auto-
immune disorders, including multiple sclerosis[13-15]. Our 
pilot studies showed that 2-CdA therapy[16] is feasible 
and well tolerated in these patients. Survival at that time 
seemed promising, but follow-up was short. 
This analysis evaluates cladribine therapy in a large 
prospectively studied open-label cohort of  RCD Ⅱ pa-
tients, during a mean follow-up time of  3 years. 
MATERIALS AND METHODS
This cohort study includes reports of  extended follow-
up of  14 out of  the 17 RCD Ⅱ patients included in the 
open-label prospective phase Ⅰ study performed by Al-
Toma et al[16] with 18 new patients added. Three patients 
out of  the previous study were not included in this 
study as they were followed over time outside our hos-
pital. Between January 2000 and April 2010, 2-CdA was 
prescribed to 32 RCD Ⅱ patients at the VU University 
Medical Centre in The Netherlands. 
Inclusion criteria
Patients diagnosed as having RCD Ⅱ and treated with one 
or two courses of  2-CdA at the VU University Medical 
Centre were included. Cladribine was intravenously given 
in a dose of  0.1 mg/kg per day for 5 consecutive days. The 
diagnosis of  RCD Ⅱ was based on persisting or recurring 
clinical symptoms and small intestinal villous atrophy af-
ter a former good response to a strict GFD, despite strict 
adherence to the diet for more than 12 mo. Furthermore, 
the clinically validated cut-off  value of  more than 20% ab-
errant intraepithelial lymphocytes (IELs) detected by flow 
cytometric (FACS) analysis was used to distinguish RCD 
type Ⅰ and type Ⅱ[5]. Although a clonal TCR gamma rear-
rangement determined by PCR is still a widely accepted 
method to define RCD Ⅱ, Verbeek et al[5] showed that the 
percentage of  aberrant IELs detected by FACS analysis is 
a more accurate way to define RCD Ⅱ. The presence of  
EATL was excluded by using selected investigations[17-20] 
and its diagnosis was confirmed according to the World 
Health Organization Classification of  Tumors of  Hae-
matopoietic and Lymphoid tissues[21]. Furthermore, pre-
treatment with immunomodulatory drugs within 6 mo or 
any experimental drug within 30 d of  the study entry was 
not allowed.
Follow-up and criteria of response
Before and during follow-up after cladribine treatment 
a clinical assessment was carried out noting in particular 
signs and symptoms of  malabsorption, body mass index 
(BMI), albumin, and haemoglobin (Hb). A nutritional 
screening was performed by a dietician who specialised in 
CD in almost all patients prior to treatment and nutrition-
al support was given when indicated. Clinical remission 
was defined as improvement of  the diarrhoea, abdominal 
discomfort and/or signs of  malabsorption, combined 
with at least 2 out of  the following parameters of  intesti-
nal integrity within the normal range or an improvement 
of  ≥ 1 point: (1) Hb; (2) BMI; and (3) albumin. Multiple 
duodenal biopsies were taken by upper gastrointestinal 
endoscopy in order to detect histopathological abnor-
malities and to perform immunophenotyping of  IELs by 
FACS analysis at different time points (planned at 3, 6 and 
12 mo, and then every year during follow-up). Isolation 
of  small intestinal T-lymphocytes and staining for immu-
nophenotyping were performed as previously described[5]. 
Complete histological remission has been defined as a 
normalisation of  the architecture of  the duodenum, clas-
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sified as a Marsh 0 or I lesion according to the Modified 
Marsh classification[22]. A decline of  20% or more in the 
percentage of  aberrant IELs was considered a significant 
immunological remission. In addition, survival rate and 
EATL occurrence were evaluated during follow-up. 
Furthermore, following on from Verbeek et al[10] who 
hypothesised that pre-treatment with common immuno-
suppressive drugs, including azathioprine and prednisone 
might influence the response to 2-CdA treatment, this 
study compared RCD Ⅱ patients pre-treated with im-
munosuppressive agents before 2-CdA was prescribed 
(group Ⅰ) to those treated with upfront 2-CdA (group Ⅱ). 
Ethical approval and informed consent 
Approval for this open label study protocol was obtained 
from the local ethics committee in 2000 and all patients 
gave their informed consent. 
Statistical analysis
Quantitative data were expressed as medians and means. 
Kaplan-Meier survival curves were constructed using 
SPSS software (SPSS Inc., Chicago, Illinois, USA). In ad-
dition, the log rank test was used to assess the statistical 
significance. A P value of  less than 0.05 was considered 
statistically significant.
RESULTS
In total, 32 RCD Ⅱ patients who were treated with 2-CdA 
were included with a median follow-up time of  31 mo 
(range 4-120 mo). Patient characteristics (Table 1) show a 
median age of  > 50 years, with a male predominance. Prior 
to the start of  2-CdA therapy, 10 patients failed to respond 
clinically and histologically to conventional immunosup-
pressive drugs (defined as group Ⅰ), including high dose 
prednisone in 2 and azathioprine or 6-thioguanine added 
to prednisone in 8 patients. The remaining 22 patients (de-
fined as group Ⅱ) were initially treated with 2-CdA follow-
ing diagnosis of  RCD. 
Disease status
In agreement with our previous study, 2-CdA was feasible 
and well tolerated without serious adverse events[10]. Over-
all, 18 (56%) of  the RCD Ⅱ patients were responsive to 
one or two courses of  2-CdA based on the clinical and 
complete histological and/or immunological response 
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Apoptosome
(Figure 2). Seven showed a clinical and histological re-
sponse, 4 a clinical and immunological response, and 7 a 
clinical, histological and immunological remission. Out of  
the remaining 14 patients unresponsive to 2-CdA, 2 were 
admitted for a second course of  2-CdA in the last 6 mo 
and in anticipation of  evaluation of  response. Six non-
responsive patients were evaluated for high dose chemo-
therapy followed by autologous hematopoietic stem cell 
transplantation (auSCT). In 2 of  them stem cells could 
not be harvested, therefore 4 patients were actually trans-
planted[23]. Another 6 patients had an expectative follow-
up, 2 of  them had an exacerbation after an initial response 
to 2-CdA for almost 2 and 3.5 years.
Table 2 shows the clinical, histological and immunolog-
ical 1- and 2-year response rates to 2-CdA treatment. In to-
tal, clinical remission was observed in 26 (81%), complete 
histological remission in 15 (47%) and immunological re-
mission in 13 (41%) of  the RCD Ⅱ patients. The median 
levels of  BMI, Hb and albumin increased from 20.9 kg/m2, 
7.8 mmol/L and 36 g/L at baseline to 23 kg/m2, 
7.9 mmol/L and 39 g/L at the end of  follow-up, respec-
tively. In addition to the 15 patients in whom complete his-
tological remission, defined as Marsh 0 or I, was observed, 
2 patients had a partial histological remission from Marsh 
3B and 3C lesions at baseline to Marsh 2 and 3A at the 
end of  follow-up respectively. The median percentage of  
intestinal aberrant IELs before 2-CdA treatment was 61% 
and declined to 56% after 2-CdA treatment. The time to a 
50% response rate was 3 years. Approximately 33% of  the 
patients lacked a clonal TCR-gamma gene rearrangement, 
although all patients had an aberrant IELs of  more than 
20%. A statistical significance between the percentage of  
aberrant IELs and the clonality status was not found. 
Analysis of  the overall response in patients pre-treated 
with immunosuppressive drugs prior to 2-CdA (group Ⅰ) 
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Figure 2  Flowchart of the response to cladribine treatment. RCD: Refractory celiac disease; 2-CdA: 2-chlorodeoxyadenosine; auSCT: autologous hematopoietic 
stem cell transplantation; EATL: Enteropathy associated T-cell lymphoma.
Table 1  Patient characteristics
Gender (M:F) 18:14
Age of CD diagnosis: median in years (range) 58.5 (38-74)
Age of RCDⅡ diagnosis: median in years (range)    64 (42-78)
Age at the start of 2-CdA treatment: median in years 
(range)
   64 (45-78)
Treatment prior to 2-CdA
None 22
Immunosuppressive drugs 10
Follow-up time: median in months (range)    31 (4-120)
HLA-DQ status
DQ2 heterozygous 17
DQ2 homozygous 12
DQ2 and DQ8   2
Unknown   1
TCR-g gene rearrangement
Monoclonal 18
Polyclonal   9
Unknown   5
Marsh classification before 2-CdA 
Marsh ⅢA 13
Marsh ⅢB 11
Marsh ⅢC   8
Intestinal aberrant IELs before 2-CdA: median in % 
(range) 
   61 (21-96)
Body mass index before 2-CdA: median in kg/m2 
(range)
   21 (16-27)
Albumin level before 2-CdA: median (range, 
reference value 35-52 g/L)
   36 (23-47) 
Haemoglobin level before 2-CdA: median in 
mmol/L (range) 
    7.8 (6.0-9.8)
2-CdA: 2-chlorodeoxyadenosine; HLA: Human leukocyte antigen; TCR: 
T-cell receptor.
Table 2  The 1- and 2-yr response rates and the median time 
to response in the pre-treated (Ⅰ) and the upfront 2-CdA 
(Ⅱ) group
Treatment
(n)
Response (%) Time to a 50% 
response rate (mo)
12 mo 24 mo
Histological 
response
Group Ⅰ  10 13 25    36
Group Ⅱ 22 20 58    24
Overall   32 10 47 36 (3-96)
Immunological1
response
Group Ⅰ  10 11 11 > 60
Group Ⅱ 22 52 58    12
Overall   32 39 41 41 (2-96)
Clinical2
response
Group Ⅰ  10 67 67      6
Group Ⅱ 22 95 95      3
Overall   32 81 81 3 (2-72)
Overall 
response 
Group Ⅰ  10 22 38    36
Group Ⅱ 22 28 43    30
Overall   32 25 41    36
1P = 0.030 and 2P = 0.058 between group Ⅰ and Ⅱ.
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and those with up-front 2-CdA treatment showed no sta-
tistical significance (log rank, P = 0.856). Immunological 
(log rank, P = 0.030) response, however, was significantly 
higher in group Ⅱ. In addition, a trend towards a higher 
clinical response in group Ⅱ (log rank, P = 0.058) was 
found. Yet, for the histological response rate a statistical 
significance was not observed (Table 2). Cox-regression 
analysis showed that the following parameters have no 
predictive value for response to 2-CdA: age at 2-CdA in-
fusion (P = 0.06), sex (P = 0.60), TCR-gamma-clonality 
(P = 0.604), and percentage of  aberrant IELs (P = 0.646), 
degree of  small intestinal villous atrophy (P = 0.610), BMI 
(P = 0.095), albumin (P = 0.936) and Hb (P = 0.953) be-
fore treatment. 
Survival 
The overall median survival was almost 4.5 years. In to-
tal, 37% (12/32) of  all included patients died, due to an 
EATL in 42% (5/12). All patients diagnosed with EATL 
(16%) died subsequently, having a median survival of  
only 4.4 mo (range 0-12 mo) after diagnosis.
The survival curve (Figure 3A) shows a statistically 
significant difference (P = 0.037) between responders and 
non-responders to 2-CdA treatment. The 3- and 5-years 
survival rate was 83% in the responding group and 63% 
and 22% in the non-responding group, respectively. One-
sixth (3/18) of  the responders died, 1 due to refractory 
disease status and 2 were diagnosed with EATL within 3 
and 9 mo after the last infusion of  2-CdA. Approximately 
65% (9/14) of  the non-responders died, 3 as a conse-
quence of  developing an EATL within 8, 12 and 44 mo 
of  2-CdA treatment (Figure2). The exceptionally delayed 
progression into EATL in the latter patient might be 
explained by treatment with high dose of  chemotherapy 
followed by auSCT 8 mo after 2-CdA treatment. The 
remaining 6 unresponsive patients died as a result of  re-
fractory disease status; 1 treated with chemotherapy and 
auSCT died after 1 year of  follow-up and 5 with expecta-
tive follow-up died despite lack of  response to 2-CdA af-
ter a median follow-up of  18 mo (range: 4.5-60 mo). The 
patient in the latter group who died 5 years after 2-CdA 
treatment had an exacerbation after an initial remission to 
2-CdA for 3.5 years and then refused further treatment. 
In addition, there was no statistical significance (P = 
0.23) between the overall survival in the pre-treatment 
group (Ⅰ) and the upfront 2-CdA treatment group (Ⅱ) 
as depicted in Figure 3B. 
DISCUSSION
Approximately half  of  RCD Ⅱ patients have an un-
favourable clinical course as a consequence of  non or 
partial response to current available therapies and sub-
sequently the progression into EATL[7,8]. For that reason 
clinicians have become increasingly interested in treating 
this condition alternatively and more effectively. How-
ever, there is no standardised approach reported so far. 
In this study a large cohort of  RCD Ⅱ patients treated 
with 2-CdA has been analyzed. 
In agreement with Al-Toma et al[16], this report describ-
ing almost twice as many patients with extended follow-
up, showed that 2-CdA is indeed feasible and well toler-
ated without serious adverse events after short and long-
term follow-up. Our data show that RCD Ⅱ patients 
responsive to 2-CdA treatment have a statistically signifi-
cant increased survival compared to those who are unre-
sponsive. Although the median follow-up time was only 
31 mo, after 1.5 year of  follow-up none of  the responders 
died compared to 4 non-responders, indicating a clear dif-
ference in survival rate. The overall 5-year survival rate of  
RCD Ⅱ patients in this analysis is 46% so far, which is in 
line with other single-centre studies[11,12], and is expected 
to improve after extended follow-up. Previous reports 
510 January 28, 2011|Volume 17|Issue 4|WJG|www.wjgnet.com
    0      12    24     36     48     60    72     84     96    108    120
      Survival (mo)
A 1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
 s
ur
vi
va
l
    0      12    24     36     48     60    72     84     96    108    120
      Survival (mo)
n  = 141    112      92      82     61       2       1
n  = 181    16       12       7       5        3      2         1
Non-responders
Responders
B 1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
 s
ur
vi
va
l
n  = 22     181      15      10     7  3        2 2
n  = 10     162      123      72      52       3       2         1
Group Ⅰ
Group Ⅱ
Figure 3  Kaplan-Meier survival curves. A: Survival rate of responders and 
non-responders to cladribine treatment (Log Rank: P = 0.037). 13 patients died 
in the 1st and 5th year; 21 patient died in the 2nd, 3rd and 4th year of follow-up; B: 
Survival rate of the pre-treatment (Ⅰ) and the upfront 2-chlorodeoxyadenosine 
(Ⅱ) group (Log Rank: P = 0.23). 14 patients died in the 1st year; 21 patient died 
in the 1st, 3rd and 4th  year;  32 patients died in the 2nd year of follow-up.
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included RCD Ⅱ patients treated with diverse steroid-like 
drugs[11,12], whereas in this study 10 RCD Ⅱ patients unre-
sponsive to such immunosuppressive drugs were included 
as well. However, unexpectedly the overall survival did 
not significantly differ between patients pre-treated with 
conventional immunosuppressive drugs (group Ⅰ) com-
pared to those with up-front 2-CdA treatment (group Ⅱ). 
Nevertheless, a clearly increased median survival rate in 
group Ⅱ was observed. The lack of  statistical significance 
might be due to the small cohort included in group Ⅰ. In 
addition, some of  the RCD Ⅱ patients treated with con-
ventional immunosuppressive drugs died before 2-CdA 
treatment could be initiated as previously reported by our 
group[24] and were therefore not included in the current 
analysis. Apart from favouring clinical course and increas-
ing survival, preventing EATL represents the ultimate 
goal of  treating RCD Ⅱ. Although treatment with 2-CdA 
could not prevent progression into EATL, compared to 
previous reports showing EATL in 32%-52% of  the RCD 
Ⅱ patients within 5 years[7,11], our results showed a much 
lower rate of  lymphomagenesis (16%), yet approximately 
50% had a 5-year follow-up. 
Furthermore, our open-label and observational data 
showed that 2-CdA is an effective treatment in obtaining 
a clinical and immunohistological response in more than 
half  of  the RCD Ⅱ patients. Previous studies reported 
a good clinical response after treatment, but histological 
response rates up to only 30% were found depending on 
the type of  treatment[11,12]. Consistent with these findings, 
a clinical response rate of  81% was found. The potential 
advantage of  2-CdA, however, seems to be a good his-
tological response. In fact, histologic healing (Marsh 0 or 
I) was observed in almost half  of  the cases and a partial 
response of  at least two Marsh scores in another 3 cases. 
Although not statistically significant, the 2-year histologi-
cal response rate in up-front 2-CdA group (Ⅱ) was twice 
that of  the pre-treatment group (Ⅰ), possibly indicating a 
beneficial effect of  up-front 2-CdA treatment. 
Furthermore, Malamut et al[11] recently described a 
74% steroid-dependency in a large cohort of  RCD Ⅱ 
patients treated with corticosteroids. Since there is no 
need for corticosteroids if  2-CdA therapy is prescribed, 
steroid-dependency and its complications will not occur.
In this cohort, the proportion of  RCD Ⅱ patients 
lacking a clonal TCR-gamma gene rearrangement was 
relatively high (33%) compared with that reported in 
other studies[4,11,12], although all patients had more than 
20% aberrant IELs determined by FACS analysis. This 
discrepancy might be the result of  some technical as-
pects of  the DNA analysis, for instance a reduced DNA 
quality due to formalin fixation of  the biopsies and a 
limited sensitivity of  PCR in the case of  a low percent-
age of  aberrant IELs. Therefore, the tested polyclonal 
status in this cohort is most likely overestimated. How-
ever, we have previously shown[5] that flow cytometry 
of  aberrant IELs is superior to clonality analysis for risk 
stratification in RCD Ⅱ.
Approximately 40% of  the RCD Ⅱ patients showed 
an immunological response after 2-CdA treatment, defined 
as a decrease of  more than 20% of  the aberrant intestinal 
IELs determined by FACS analysis. However, the majority 
still showed more than 30% aberrant IELs during follow-
up. Expansion of  these aberrant T-lymphocytes, which 
reside in the intraepithelial as well as lamina propria layer 
of  the small intestine[25], is generally accepted as the culprit 
factor in the progression into EATL. Conversely, in our 
series the persisting high percentage of  aberrant mucosal 
T-lymphocytes did not correlate with the relatively low 
EATL occurrence found during the time of  follow-up so 
far. Unfortunately, reports from other centres on the im-
munological response determined by FACS analysis after 
treatment are lacking. Whereas the percentage of  aberrant 
IELs is established to be important in the diagnostic work-
up for distinguishing RCD type Ⅰ and Ⅱ[5], apparently 
it is questionable whether this percentage is a predictive 
marker for progression into EATL during monitoring of  
the therapeutic response. Further research is mandatory to 
further elucidate EATL risk stratification. Immunopheno-
typing of  the aberrant T-cells by FACS analysis of  small 
intestinal biopsies and probably also genotyping seem to 
be appropriate methods to search for predictive markers. 
In addition, future studies on quantifying the mass of  ab-
errant IELs using immuno-PET techniques, instead of  the 
currently determined percentage of  aberrant IELs, given 
the relatively equal depletion of  normal and aberrant IELs 
upon 2-CdA treatment, have to be conducted.
In the current analysis approximately half  of  the 
RCD Ⅱ patients were unresponsive to 2-CdA, for yet un-
known reasons. A significant association with the degree 
of  mucosal villous atrophy, the percentage of  aberrant 
IELs, and levels of  BMI, Hb and albumin before 2-CdA 
treatment, clonal TCR-gamma gene rearrangement and 
HLA-DQ status was not revealed. Although dose-finding 
studies with 2-CdA infusion in refractory celiac disease are 
not conducted, clinical dose-finding studies in lymphop-
roliferative diseases showed good response rates with an 
identical treatment schedule[13,26]. In addition, compared 
to intravenous infusions and subcutaneous injections 
which provide identical plasma 2-CdA levels, oral admin-
istration has a much lower bioavailability (approximately 
40%) due to degradation through acid in the stomach and 
intestinal bacteria[14]. A higher dose and/or a prolonged 
treatment schedule might result in a higher response rate, 
yet the maximum tolerated dose established in lympho-
proliferative diseases without serious adverse events was 
0.1 mg/kg per day for 7 d[13]. A recent clinical trial of  oral 
cladribine for relapsing multiple sclerosis showed that 
short-course and high dose (3.5 mg/kg) therapy is effec-
tive, yet lymphocytopenia is frequently reported[15]. Fur-
thermore, the high sensitivity of  hairy cell leukaemia (HCL) 
to treatment with 2-CdA showing low resistance levels is 
hypothesised to be the result of  p53-dependent pathways 
required for killing resting cells and its inhibitory effect on 
the cholesterol metabolism which is highly active in HCL 
cells[14]. Physiological conditions such as increased repair 
of  DNA, increased anti-apoptotic effects and decreased 
activation of  deoxycytidine kinase, an enzyme required for 
the cytotoxicity of  2-CdA, might be contributing factors 
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to resistance as well[27]. Whether the same results regarding 
administration route, treatment schedule and resistance 
pattern of  2-CdA also correlate with such good response 
rates in RCD Ⅱ, remains to be further elucidated. The 
registration of  oral 2-CdA for multiple sclerosis in Eu-
rope, might be a further step forward towards the ap-
plication of  this drug in RCD as well as some other gas-
troenterological diseases refractory to currently available 
therapies, including Crohn’s disease, ulcerative colitis and 
autoimmune hepatitis.
In conclusion, 2-CdA appears to be a promising treat-
ment in RCD Ⅱ. This analysis showed excellent clinical 
and histological response rates after 2-CdA treatment. 
Furthermore, 2-CdA therapy does not necessitate the ad-
ditional use of  corticosteroids and subsequently prevents 
steroid-dependency and its complications. Although 
EATL could not be fully prevented, its incidence was 
restricted to 16%. Multicentre, randomised clinical tri-
als with 2-CdA and/or other new treatment options are 
mandatory to standardise the treatment strategy for RCD 
Ⅱ, in order to further decrease morbidity and mortality in 
this patient group. 
COMMENTS
Background
A small percentage (2%-5%) of patients with adult-onset celiac disease, espe-
cially those diagnosed above the age of 50, show a lack of response to a gluten-
free diet. They are diagnosed as suffering from refractory celiac disease (RCD) 
when clinical and histological symptoms persist or recur after a former good re-
sponse to a strict gluten-free diet and despite strict adherence to the diet for more 
than 12 mo, unless earlier intervention is necessary. RCD can be subdivided 
into type Ⅰ with phenotypically normal and type Ⅱ with aberrant intraepithelial 
T lymphocytes in the small intestinal mucosa. Patients with RCD Ⅰ have a less 
dismal prognosis compared with those diagnosed as having RCD Ⅱ: the 5-year 
survival rates are 96% and 58%, respectively. As the majority of RCD type Ⅱ 
patients are unresponsive to common immunosuppressive therapy, it is of utmost 
importance to evaluate new treatment strategies. Apart from clinical and histologi-
cal remission, the ultimate goal of treatment is to prevent progression into a lethal 
enteropathy associated T-cell lymphoma (EATL) which occurs in more than half 
the patients within 4-6 years. 
Research frontiers
This is the first report evaluating a standardised treatment strategy for RCD 
type Ⅱ with cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in a large 
cohort (n = 32) with a long-term follow-up (median 31 mo). 
Innovations and breakthroughs
This report shows that cladribine was feasible and well tolerated without seri-
ous adverse events. More than half of the RCD Ⅱ patients were responsive to 
cladribine therapy and had a significantly increased 3 and 5 year survival com-
pared to those who were unresponsive. In line with previous reports, very high 
clinical response rates were observed. The potential advantage of cladribine, 
however, seems to be a good histological response. In fact, histologic healing 
(Marsh 0 or I) was observed in almost half of the cases and a partial response 
of at least two Marsh scores in another 3 cases, compared to reported histo-
logical response rates up to only 30%. Although EATL could not be fully pre-
vented, its incidence was restricted to 17%. Furthermore, 2-CdA therapy does 
not necessitate the additional use of corticosteroids and subsequently prevents 
steroid-dependency and its complications. 
Applications 
The results suggest that cladribine therapy may represent a promising option 
for RCD Ⅱ, however, multicentre randomised clinical trials with 2-CdA and/or 
other new treatment options are mandatory to standardise the treatment strat-
egy for this group, in order to further decrease morbidity and mortality in this 
patient group. 
Terminology
Aberrant IELs: Intraepithelial T lymphocytes are considered aberrant when 
expressing cytoplasmic CD3, but lacking surface expression of the T-cell 
markers CD3, CD4, CD8 and the T-cell receptor. 2-CdA: Cladribine, 2-chloro-
deoxyadenosine, a synthetic purine nucleoside homologue. EATL: Enteropathy 
associated T-cell lymphoma. RCD: Refractory celiac disease. Immunologically, 
this disorder can be subdivided into two types: type Ⅰ without and type Ⅱ with 
aberrant IELs in the small intestinal mucosa. TCR: T-cell receptor.
Peer review
In this manuscript, the authors reported an open-label study on the treatment 
of type Ⅱ refractory coeliac disease (RCD Ⅱ) with cladribine (2-chlorodeoxy-
adenosine) in a cohort of 32 patients. After a mean follow up time of 3 years, 
cladribine, which was given to 22 patients as the first line treatment and 10 
patients who failed to respond to conventional immunosuppressive drugs, 
was shown to have induced apparent clinical, histological and/or immunologi-
cal response in over half of the patients. In addition, all the responders had 
a significantly increased 3 and 5 year survival compared to those who were 
unresponsive although progression of RCD-Ⅱ to enteropathy associated 
T-cell lymphoma had not been prevented and overall 5 year survival (46%) was 
not different from that reported by other centres using alternative therapies. 
This open-label trial was uncontrolled. However, a favourable outcome was 
observed in most of patients treated with cladribine. The results suggest that 
cladribine therapy may represent a promising option for RCD Ⅱ patients.
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